Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 PS1-05-03 | DOI: 10.1530/endoabs.101.PS1-05-03

1University Medical Center Groningen, Endocrinology, Groningen, Netherlands; 2University Medical Center Groningen, Endocrinology / Surgical Oncology, Groningen, Netherlands; 3University Medical Center Groningen, Radiation Oncology, Groningen, Netherlands; 4University Medical Center Groningen, Radiation Oncology; 5University Medical Center Groningen, University Medical Center Groningen, Surgical Oncology, Groningen, Netherlands; 6University Medical Center Groningen, University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging Groningen, Groningen, Netherlands; 7University Medical Center Groningen, Groningen University, Groningen, Netherlands; 8University Medical Center Groningen, University Medical Center Groningen, Surgery, Groningen, Netherlands; 9University Medical Center Groningen, Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Department of Endocrinology, Groningen, Netherlands


Objectives: To analyze acute and late toxicities and long-term quality of life (QoL) in patients who underwent locoregional external beam radiotherapy (EBRT) for thyroid cancer and to assess the correlation of QoL with treatment characteristics.

Methods: Patients treated with locoregional EBRT for thyroid cancer at University Medical Centre Groningen (UMCG) (2007-2023) were included. Patient/treatment characteristics were extracted from patient files retrospectively. Acute (<6 weeks) and late (≥3 months) toxicities and QLQ-H&N35 results (pre-radiation and 6 months post-radiation), collected as standard part of patient care, were extracted from a prospective database. Additionally, living patients were asked to complete QLQ-H&N43 (renewed QLQ-H&N35 version) and SF-36-RAND-36, allowing a longitudinal comparison. Correlations were evaluated between questionnaire scores and EBRT techniques (IMRT vs VMAT) and other treatment characteristics.

Results: For the retrospective analysis, 66 patients were studied. In a subset of 31 patients that completed the questionnaires during EBRT prospectively, acute toxicities included: dermatitis (93%), pain (74%), hoarseness (71%), dysphagia (67%), tough mucus (56%), xerostomia (52%), change of taste (27%), and mucositis (26%). Late toxicity presented as persisting acute toxicity and fibrosis (65%). After six months, the QLQ-H&N35 domains ‘social eating’ (P = 0.031) and ‘dry mouth/sticky saliva’ (P = 0.025) were impaired, in comparison to pre-radiation. 25 of the 66 patients were alive at time of data collection and 17 of them filled in the two additional questionnaires. Long-term mitigation was not observed for the 10/17 patients that completed both QLQ-H&N35 and QLQ-H&N43. For the treatment characteristics, only VMAT was associated with an improved QLQ-H&N43 score, compared to IMRT (P = 0.047).

Conclusion: EBRT causes acute and late toxicities in most thyroid cancer patients and creates a decrease in their QoL. As these patients generally have relative high survival rates, there is a compelling need to minimize toxicities with more refined radiation techniques, such as proton therapy.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.